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Parkinson’s disease is, at the neuropathological level, characterized by the death of dopaminergic 
neurons. PD pathogenesis is multifactorial, there are several mechanisms that malfunction 
leading to the death of dopaminergic neurons. The mitochondria are vital for the normal 
functioning of a cell, they are the primary energy generator for the cell. In addition to their 
energy metabolism role, mitochondria are involved in many cellular processes, such as the stress 
response and cell death pathways. As a result, mitochondrial impairment and the genes that are 
related to its functionality are linked to progressive neurodegeneration. Considering parkin, 
PINK1, DJ-1, and LRRK2 gives insight into how PD develops and potential therapeutic options. 
Mitochondrial dysfunction works in conjugation with another classic PD characteristic, the 
accumulation of misfolded proteins. ER stressed caused by the accumulation and formation of 
aggregates induces a cellular defense mechanism, UPR; however, chronic ER stress impairs 
many of the protective functions that the cell possesses leading to cell death. Individually 
mitochondrial dysfunction and ER stress have been implicated in PD, but their interaction is not 
entirely understood. Furthermore, the role of key mitochondrial related PD genes in 
mitochondria-ER stress resulting in dopaminergic neurodegeneration has not been fully 




Parkinson’s disease (PD) was first described as “shaky palsy” in 1817 by Dr. James Parkinson. It 
is a chronic, progressive, neurodegenerative disease with motor and nonmotor features. The 
disease is characterized by the loss of dopaminergic neurons and the subsequent deficiency of 
dopamine in the striatum [7]. The motor symptoms that manifest is resting tremors, bradykinesia, 
and muscle rigidity. These motor symptoms have been grouped into a symptom complex called 
parkinsonism [10]. Research has shown that pathophysiological changes that underlie PD may 
start before the onset of the motor issues. A number of nonmotor symptoms present before the 
motor, such as sleep disorders, depression, and cognitive changes [11]. There are different 
classifications of PD, familial and sporadic. A hallmark of sporadic PD is the presence of 
proteinaceous aggregates in Lewy Bodies. However, there have not been consistent findings that 
LBs play a part in familial PD. Misfolded proteins usually trigger a cellular response in the 
endoplasmic reticulum (ER) called the Unfolded Protein Response (UPR). The formation of 
these Lewy bodies suggests that some impairment in the cell’s normal protein degradation 
mechanism.  
 
The cause of sporadic PD is not as simple as some aggregates of a protein, it has been 
determined to be a multifactorial disorder that consists of several types of proteins and 
dysfunction in many different biochemical pathways. The different proteins that have been 
identified to have a role in the development of LBs are a-Synuclein, ubiquitin, and molecular 
chaperones [16]. Environmental factors and genetic susceptibility need to also be considered. 
Research into PD genes has shown that mutations in mitochondrial genes are responsible for 
monogenic familial forms. The unique biochemical environment that the mechanism of oxidative 
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respiration makes the mitochondria vulnerable for genetic mutations. The death of dopaminergic 
neurons that is emblematic of parkinsonism is intertwined in many cell systems. There are many 
pathways that a cell can take to remove a stressor or neurotoxic substances and dysfunction in 
more than one of them can compound leading to PD. Within mitochondrial dysfunction there are 
several proteins that are involved in pathogenesis, such as -Synuclein, parkin, PINK1, and DJ-
1. Genetic markers are the latest factors to be considered for the etiopathogenesis of PD, 
especially the genetic mutations in the mitochondria [7]. 
 




Parkinson’s disease is a disorder of the extrapyramidal system, it includes the motor structures of 
the basal ganglia. PD is characterized by the loss of dopaminergic function and diminished motor 
function leading to the clinical manifestations of the disease [11]. The striatal dopamine loss has 
been identified as the major cause of the major symptoms of PD. However, the nonmotor 
symptoms suggests that other neurotransmitters are involved, such as the glutamatergic, 
cholinergic, serotonergic, and adrenergic systems. Neuromodulators adenosine and enkephalins 
have also been proposed as having a role [10]. Further evidence suggests that PD may start in the 
dorsal motor nucleus of the vagal and glossopharyngeal nerves and in the anterior olfactory 
nucleus, indicating pathogenesis in the brain stem that continues to higher cortical levels. The 
histopathological features of PD include the loss of pigmented dopaminergic neurons and the 
presence of Lewy bodies (LBs) [12]. Degeneration of the dopaminergic neurons in the substantia 
nigra pars compacta (SNpc) occurs progressively, which then project to the striatum. Patients 
experience motor symptoms of PD after they have lost 50%-80% of the dopaminergic neurons. 
Two types of dopamine receptors are responsible for the motor component of the extrapyramidal 
system, D1 (excitatory type) and D2 (inhibitory type). This system includes the basal ganglia, 
which incorporates the internal globus pallidal segment (GPi) of the ventral striatum, and the 
substantia nigra pars reticulata (SNpr). Dopamine loss in PD patients causes increased activity in 
the GPi/SNpr circuits, which leads to GABA dysfunction and thalamus inhibition. The end result 
of thalamus inhibition is its inability to adequately activate the frontal cortex, resulting in the 
decreased motor activity [13]. However, PD is a complex neurodegenerative disease that 
involves several biochemical pathways, and it is the interaction of these pathways that lead to 
neuropathology of the disease [65].  
 
1.2 Lewy Bodies 
 
A major feature of PD is the presence of LBs. LBs are described as intracellular cytoplasmic 
aggregates made up of proteins, lipids, and other materials. In patients with PD, LBs are found in 
the dopaminergic neurons in the substantia nigra as round bodies with radiating fibrils. It is 
suggested that the formation of LBs may be secondary to refractory proteolytic processes 
involving abnormal breakdown or overproduction influenced by genetic mutations [12]. Gene 
mutations involving -Synuclein have been found to aggregate and form insoluble fibrils 
associated with LBs; -Synuclein has now been identified as a potential therapeutic target for 
PD therapy [14]. The formation of LBs involves excess production of a misfolded form of 
ubiquitin protein. Ubiquitin has a role in protein recycling. The accumulation of ubiquitin occurs 
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as a result of the malfunction of the ubiquitin proteasome system (UPS) [10]. However, there are 
many mechanisms that lead to the malfunction of the UPS. Mitochondrial dysfunction, ER stress, 
and proteotoxic stress, to name a few. One of the proteins that link the formation of LBs with the 
mitochondria is the LRRK2 protein, which has been found to be present in LBs [96]. LBs appear 
to play a role in the neurodegeneration that is characteristic of PD. The lesion patterns are 
consistently seen at various stages of the disease. These patterns are located in the dorsal 
nucleus, medulla, and pons, and may support early premotor features (olfactory and rapid eye 
movement) of PD [15]. LB formation is not likely to be the cause of one malfunction or 
aggregation of one protein. There is a large network of interacting mechanisms that contribute to 
the homeostasis of the dopaminergic neurons. However, deficiencies in one area of maintenance 
may lead to a cascade of neurotoxic damage resulting in inadequate protein removal that is 




 -Synuclein Structural Properties 
 
-Synuclein is a 140 amino acid protein found in the brain. It is present primarily in both the 
soluble and membrane-associated fractions of the brain [1]. -Synuclein is a part of the 
synuclein family along with the  and  forms. These three forms of synuclein are neuronal 
proteins that typically localize at the presynaptic terminal under normal physiological conditions 
[2]. In an aqueous solution the protein has no defined structure. -Synuclein is composed of 
three different regions, an amino terminus that has apolipoprotein lipid-binding motifs, a central 
hydrophobic region, and a carboxyl terminus that is highly negatively charged [2].  It has been 
described as a “natively unfolded protein”. -Synuclein’s unfolded structure is determined by its 
relatively low hydrophobicity and high net charge [1]. The polarity and charge of -Synuclein 
allows the protein to interact with water to a higher degree. The protein typically is an aqueous 
solution and its interaction with water reduces the hydrophobic effect, maintaining the “unfolded 
structure”. owever, -Synuclein does conform to particular structures under particular 
conditions, it adopts -helical structures when binding to negatively charged lipids and has -
sheet rich structures when incubated for prolonged periods of time [2]. Changing the protein 
environment in such a way to increase the hydrophobicity and/or decrease the net charge has 
been shown to induce some partial folding [1]. There are several methods that can be employed 
to try and modulate the environment around -Synuclein to induce different structural patterns. 
The high negative charge at physiological neutral pH can be neutralized by acidifying the 
solution, and the hydrophobicity can be increased with higher temperature [6]. Later experiments 
confirmed that the when the pH was reduced to 3.0 or the temperature was increased, -
Synuclein gained a more ordered secondary structure, became more compact, and developed a 
semblance of a tightly packed nucleus [6]. The relative compactness of -Synuclein under the 
non-physiological conditions was a result of clustering due to the hydrophobic effect of the polar 
residues of the protein [2]. Because the structure of -Synuclein is natively unfolded, there is 
partial misfolding of -Synuclein in certain regions for functional purposes. 
 
 -Synuclein Function 
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The function of -Synuclein is not entirely understood, but many of the functions that are 
proposed relate to its structure and the interactions that it makes [1-3]. Many different functions 
have been suggested to be attributed with -Synuclein, including synaptic vesicle release and 
trafficking, fatty acid binding, physiological regulation of certain enzymes, transporters, and 
neurotransmitter vesicles, as well as neuronal survival [1]. Neuronal survival is of vital 
importance when discussing -Synuclein in the context of neurodegenerative disease, 
particularly Parkinson’s. There are three groups in the Synuclein family,   and , knockout of 
these genes in vertebrates leads to neuronal dysfunction [1,4]. This indicates that -Synuclein 
plays a role in stabilizing long-term operation of the nervous system. -Synuclein was shown to 
protect against -Synuclein degeneration leading to neurodegenerative diseases [2]. -Synuclein 
has also been shown to physically interact with at least 30 proteins, underlying its important role 
in cell to cell signaling [1,2]. Diseases that results from -Synuclein pathology typically affect 
neurophysiology, indicating that the functions of -Synuclein have to do with brain function.   
-Synuclein can potentially be a down regulator for the enzyme tyrosine hydroxylase (TH). TH 
activity modulates the production of dopamine and its control at cellular levels. The interaction 
between -Synuclein and TH is not direct [4]. Tyrosine hydroxylase is normally phosphorylated 
when active; however, through the action of -Synuclein and its interaction with PP2A, a 
phosphatase, TH is dephosphorylated at the Ser40 residue and is inactivated [4,5]. This stops the 
enzyme from converting tyrosine to L-dopa a precursor for dopamine.  
 
  -Synuclein Dysfunction 
 
There are two structural classes of amyloid fibrils: those derived from folded proteins and those 
derived from intrinsically disordered protein. These amyloid fibrils are formed from the folded 
proteins by either the refolding mechanism or by the gain-of-interaction model [8]. -Synuclein 
belongs to the second class of amyloid fibrils, it is intrinsically disordered amyloid protein that 
forms fibrils by converting some or all of the polypeptide into well-defined, beta-sheet rich 
secondary structure. The beta-sheets easily form a cross-beta structure, in which the beta-sheets 
are arranged in parallel, with highly ordered amino acid side chain patterns exposed on the 
surface of the beta-sheets [8,9]. The sidechains from the beta-sheets interdigitate in a self-
complementary manner to give rise to highly ordered steric zippers. The formation of steric 
zippers is not unique to -Synuclein fibrils, but the morphology of -Synuclein fibrils exhibit a 
distinct structural polymorphism. These differences come from the unique structure of -
Synuclein and the interactions its sidechains have with the environment [2]. Changes in the 
buffer solution seem to be factor in the rate of folding and aggregation, like pH, temperature, ion 
concentration, and external variables such as agitation or toxins. The potential of -Synuclein to 
form this beta-sheet structure is reminiscent of the beta-sheets of -amyloid, which provides a 
pathogenetic basis for two neurodegenerative diseases [1]. In Parkinson’s disease -Synuclein is 
heavily expressed within Lewy bodies, in particular, in the “halo” of the inclusions [53,54]. -
Synuclein fibrils form the basis for mature LBs present in synucleinopathies, however in the 
process of fibril formation, intermediates forms develop. The early intermediate forms are 
soluble and have different oligomeric characteristics, such as sphere-like, ring-like, and string-
like. These protofibrils eventual coalesce into fibrils and become insoluble [55]. The insoluble 
fibrils combine and cannot be removed, which leads to the generation of -Synuclein aggregates, 
this aggregation is the main pathogenic component of -Synuclein [2]. Research into the 
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different variants of -Synuclein have shown that there are species that are more vulnerable to 
the generation of fibrils. A53T and A30P -Synuclein adopt the protofibril conformation than 
their wild-type counterparts and among the two, A53T more readily converts into a mature fibril 
[56]. Dopamine and its metabolites act as inhibitors for the conversion of protofibrils into their 
mature forms. The loss of the dopaminergic neurons in the pathogenic process of PD decreases 
availability of these substances and the increased presence of protofibrils [57]. There are several 
proposed mechanisms that -Synuclein aggregates can be neurotoxic. Populations of -
Synuclein can induce toxicity directly and/or mediate toxicity through various mechanisms using 
proteins involved in different cellular processes [50]. The neurotoxicity of -Synuclein and its 
aggregates can be grouped into three classes: mechanical disruption of cellular 
compartments/processes, toxic gain of function, and toxic loss of function [51]. A common 
method that disruption occurs is permeation of cellular membranes by the amyloid aggregates. 
-Synuclein binds to lipid membranes and disrupt membrane bilayers by utilizing pore-like 
channels [52]. -Synuclein gain of function is associated with PD pathogenesis stemming from 
experiments that showed a dose-dependent correlation of -Synuclein accumulation to the PD 
phenotype. Features of the disease were shown in when WT overexpression of -Synuclein was 
induced [2]. However, it is generally assumed that -Synuclein gain of function is inherent 
within the normal protein, but a toxic component arises when the concentration exceeds a certain 
level. This was evident when comparing -Synuclein knockout mice with mice that 
overexpressed the protein and there was no overt neuropathological or behavioral phenotype 
[58,59]. Perhaps the most pertinent location that -Synuclein exerts its pathogenic effects would 
be at the synapse. While there has been evidence to suggest that -Synuclein induces 
neurotoxicity in cells, the exact mechanism it uses is fragmented. The effects that are observed at 
the synapse are loss of presynaptic proteins, decrease of neurotransmitter release, redistribution 
of SNARE proteins, enlargement of synaptic vesicles, and inhibition of synaptic vesicle 
recycling [60]. -Synuclein has been shown to utilize a pore-forming mechanism to disrupt 
cellular compartments, one compartment that -Synuclein may target at the synapse are the 
synaptic vesicles. These pores leak out dopamine into the cytosol and its build up leads to 
oxidative stress induced cell death [52,61]. -Synuclein also mimic the characteristics of other 
mitochondrial toxins, it plays a role in the downregulation of complex I. -Synuclein has been 
shown to reside, in some quantities, within mitochondria [62]. The effects that -Synuclein has 
on the mitochondria have cell wide implications and induce a variety of other protein 
dysfunction. -Synuclein appears to induce mitochondrial fragmentation and may be a casual 
factor in mitochondrial dysfunction and death [63]. Possibly through this mechanism of 
fragmentation -Synuclein also appears to induce excessive mitophagy, leading to inappropriate 
mitochondrial removal [64]. These effects place the mitochondria under stress, especially 
inhibiting complex I function, leading to oxidative stress, generating reactive oxygen species and 
eventual neuronal death.  
 




The mitochondria are the site of ATP synthesis through the electron transport chain. The 
transport of electrons involves movement through 4 complexes and a series of coupled redox 
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reactions. These reactions provide the energy to pump hydrogen ions from the mitochondrial 
matrix into the intermembrane space, thus creating an electrochemical gradient. This gradient has 
an electrical potential that used to drive the conversion of ADP to ATP [7]. Complex I is the 
primary gateway for electrons to enter the respiratory chain [17]. Complex I is responsible for 
the electron transfer of NADH to ubiquinone and this action is coupled to the movement of four 
protons from the mitochondrial matrix to the intermembrane space [18]. Because mitochondria 
action is closely linked with oxygen and hydrogen, (in the form of protons, which can be acidic) 
it is an important source of reactive oxygen species (ROS) [18,19]. Complex I, and to a lesser 
degree complex III, are the primary sites of ROS generation. They are responsible for 
transferring a single electron to oxygen thus creating a superoxide anion. This superoxide anion 
is the proximal ROS, mainly produced in the mitochondrial matrix. It is quickly converted to 
hydrogen peroxide (another ROS) by MnSOD. In the presence of Fe2+, hydrogen peroxide can 
be converted into a highly reactive hydroxyl radical [20,21]. This increased concentration of 
ROS and/or the cell’s inability to remove it, results in oxidative damage to mtDNA, proteins, 
lipids, and interferes with the redox signaling pathways. Oxidative damage to the mtDNA causes 
mutations that further damage components of the respiratory chain leading to a continuous cycle 
of oxidative stress [20]. Mitochondrial DNA (mtDNA) is a double-stranded circular genome of 
about 16.6 kb, and it replicates independently from the cell cycle and nuclear DNA replication 
[7]. mtDNA encodes for 13 proteins, all of which are components for the respiratory chain 
complex; seven subunits are for complex I, one subunit for complex III, three subunits of 
complex IV, and two for ATP synthase. mtDNA codes for 22 tRNAs and two rRNAs that are 
used to create the proteins [22]. However, these are not all of the proteins that mitochondria 
require. Mitochondria require about 1500 different proteins, a majority of mitochondrial proteins 
are encoded by nuclear DNA, translated in the cytoplasm and imported into the import 
machinery [23]. Thus, there are many genes and mechanisms that can be affected by mutations 
and cause mitochondrial dysfunction. Typically, mutations in the mitochondrial genome are 
symptomatic in postmitotic cells that have a high energy demand, such as neurons [22]. mtDNA 
is characterized by an increased vulnerability to mutations, it contains less efficient DNA repair 
mechanisms and lacks protective histones; as stated before, mitochondria generate reactive 
oxygen species and it is speculated that mtDNA’s proximity to the respiratory chain favors 
mtDNA damage [24]. These mutations can proliferate through clonal expansion either in 
daughter mitochondria or daughter somatic cells, until the mutations reach a certain threshold 
and respiratory deficiency occurs [25]. Dopaminergic neurons from the substantia nigra have 
shown an age-dependent increase in somatic mtDNA, shown through long range PCR and 
quantitative real time or single molecule PCR. Levels of mtDNA deletions were slightly higher 
in dopaminergic neurons of PD patients when compared to age-controlled models [7]. A link 
between mtDNA and neurodegeneration has been further substantiated by genetic mouse models. 
A knockout of TFAM in midbrain dopaminergic neurons caused reduced mtDNA expression, 
respiratory chain deficiency, and neuronal cell death, leading to progressive L-dopa-responsive 
impairment of motor functions [26]. -Synuclein was the first gene that was described to be 
associated with familial PD, since then four other genes have conclusively been linked to 
autosomal recessive or dominant parkinsonism. Parkin, PINK1, DJ-1 are associated with 





The gene encoding the E3 ubiquitin ligase parkin (PARK2) was identified as a causative gene for 
familial early onset parksonism [27].  Parkin’s structure has been difficult to gain insight into, 
due to its high cysteine content. This high cysteine content (35 of 465 amino acid residues) 
rendering parkin prone to misfolding and preventing the native folding of soluble recombinant 
parkin [29]. The natively folded protein contains a ubiquitin-like domain (UBL) at the N-
terminus and an RBR domain near the C-terminus, consisting of two RING finger motifs, 
RING1 and RING2, that flank the cysteine-rich in between RING finger domain [28,30]. The 
RBR domain is conserved among a specific class of proteins that have E3 ubiquitin ligase 
activity [7]. Parkin belongs to this RBR class of E3 ubiquitin ligase, which combines features of 
RING and HECT E3 ligases to attach the ubiquitin to substrates. RING ligases are used as 
scaffolds to facilitate the direct transfer of ubiquitin from a ubiquitin charged E2 to the substrate, 
while HECT ligases utilize a thioester intermediate with ubiquitin using a catalytic cysteine 
residue. RING and HECT are the two defined classes of ubiquitin ligases, however, it has been 
identified that parkin utilizes a RING/HECT hybrid mechanism [28]. The two critical regions, 
active cysteine in RING2 (C431) and the E2-binding site in RING1, are blocked by 
autoinhibition [31,32]. This autoinhibition is mediated by two structural elements: RING0 buries 
the catalytic C431 in RING2 by sharing a hydrophobic interface with RING2. The other 
structural element is a flexible linker between the IBR and RING2 at opposite sides of the 
molecule. This linker forms a helix that serves as the repressor element of parkin (REP). REP 
binds to RING1 and prevents the interaction between RING1 and E2 containing ubiquitin [28]. 
A well-known function of E3 ubiquitin ligases is its targeting substrate proteins for proteasomal 
degradation by the covalent attachment of ubiquitin [28]. Parkin serves as a neuroprotective 
protein. Parkin protects cells against a wide range of stressors, including mitochondrial 
dysfunction, excitotoxicity, endoplasmic reticulum stress, proteasome inhibition, and 
overexpression of -Synuclein [30,33]. It is hypothesized that parkin mediates its activity by at 
least three mechanisms, promoting the removal of damaged mitochondria via mitophagy, 
increasing proteasomal degradation of toxic substrates, and/or modulating nondegradative 
ubiquitin signaling within cell death or viability pathways [28]. One of the roles that parkin has, 
as it relates to the mitochondria, is its prevention of mitochondrial swelling and cytochrome c 
release [34]. In addition, parkin protects mtDNA from oxidative damage and stimulates mtDNA 
repair [35].  
 
3.2.1 Parkin Dysfunction 
 
Studies revealed that pathogenic mutations in these ubiquitin ligases, especially parkin, result in 
the accumulation of parkin substrates. The concentrated aggregates cause neurotoxicity and the 
death of dopaminergic neurons [7]. A particular study analyzed mitochondrial features in tissues 
of parkin mutant patients, specifically measuring complex I and IV activity in isolated leukocyte 
mitochondria. Among patients with parkin mutations and sporadic PD patients, there was a 
significant decrease (about 60%) in complex I activity; however, decreases on complex IV 
activity was only observed in sporadic PD patients [36]. The decreased function of these 
complexes leads to impaired energy production in the mitochondria and metabolic stress 
throughout the cell. Cultured fibroblasts from parkin patients showed functional mitochondrial 
defects. Membrane potential decreased by 30%, complex I activity by 45%, ATP production by 
58% and an increase in rotenone-induced mitochondrial fragmentation [37]. In a separate study 
parkin mutant fibroblasts were characterized by a 22% reduction in the mtDNA copy number 
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and increased vulnerability to mtDNA damages from oxidative stress [35]. Parkin has a specific 
role in the targeting of substrate proteins for degradation. Parkin has an intrinsic vulnerability to 
misfolding, this in addition, to its association with mitochondria and oxidative stress, makes it 
susceptible to loss-of-function. Evidence from cellular and animal models suggests that parkin 
mutations leads to the accumulation of neurotoxic parkin substrates can induce cellular 
dysfunction and degeneration of dopaminergic neurons, indicative of PD pathogenesis [28]. One 
example of this accumulation comes from a mouse model, where transgenic overexpression of 
aminoacyl-tRNA synthetase complex-interacting multifunctional protein-2 (AIMP2) leads to 
age-dependent selective loss of dopaminergic neurons and motor deficits [38]. Another parkin 
substrate, parkin-interacting substrate (PARIS), showed the same selective degeneration of 
dopaminergic neurons when accumulated. PARIS transcriptionally represses a peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1). PGC-1 is an important 
mediator of mitochondrial biogenesis and controls general mitochondrial maintenance. PARIS 
normal action is the stimulation of mitochondrial biogenesis by serving as a coactivator for 
various transcription factors. In this model, PARIS accumulation from parkin loss of function 




PTEN-induced kinase 1 (PINK1) is a 581-residue protein, containing an N-terminal 
mitochondrial targeting sequence, a transmembrane helix, a serine/threonine kinase domain, and 
a C-terminal domain with unknown function [40]. Mutations in PINK1 is one of the factors 
responsible for autosomal recessive PD. No crystal structure of PINK1 has been established, 
which makes it difficult to pinpoint the exact mechanism that it utilizes. However, it contains a 
conserved serine/threonine domain that resembles other kinase domains [41]. The protein shares 
the most structural features with the calmodulin-dependent kinase family. The kinase domain 
contains N- and C-terminal lobes, consisting of smaller subdomains, seen in most kinases. 
However, PINK1has three loop inserts in the N-terminal lobe. These loop inserts are some of the 
mutation sites for PD [42]. PINK1’s kinase domain also contains an activation loop with two 
serine residues, these residues play a role in the activation of the protein kinase when 
phosphorylated. The activation loop also contains Arg407, which is a potential site of interaction 
with the phosphorylated serine and a PD mutation site [40]. One of the mechanisms that is used 
to regulate kinase activity is by homo-dimerization of the kinase. It was established that wildtype 
PINK1 exists as a dimer [72,73]. PINK1 is activated in cells upon mitochondrial membrane 
depolarization, but the exact mechanism is unknown. It is synthesized outside of the 
mitochondria and imported through the outer and inner membrane of the mitochondria for post-
translational modification [43]. Mitochondrial import of PINK1 is driven by the inner membrane 
proton gradient, thus membrane depolarization leads to the accumulation of unprocessed PINK1 
at the outer mitochondrial membrane [44]. PINK1’s position at the outer mitochondrial 
membrane allows its kinase domain to face the cytoplasm (when unprocessed) and enable it to 
phosphorylate cytosolic and outer membrane substrates. PINK1 can act as a “surface receptor” 
linking its activity to the condition of the mitochondria and detect damaged mitochondria 
[40,45]. Animal studies in Drosophila indicated that PINK1 plays a role in the maintenance of 
mitochondria, and its role is closely linked to parkin [46,47]. As a function of its maintenance of 
mitochondria, PINK1 was shown to regulate HtrA2, a mitochondrial protease that plays a role in 
mitochondrial homeostasis and regulating mitochondrial morphology [48,49]. One of the 
 9 
proteins that is phosphorylated by PINK1 is TRAP1 (TNFR-associated protein 1; heat shock 
protein 75). TRAP1 phosphorylation is essential for PINK1’s protective activity against 
oxidative stress [67]. A functional link between PINK1 and HtrA2/Omi has also been 
established. HtrA2/Omi is a mitochondrial serine protease that is activated by apoptotic stimuli 
and released into the cytosol, where it interacts with inhibitor of apoptosis proteins. HtrA2/Omi 
is most likely phosphorylated by the p38 kinase pathway, but some direct interaction with 
PINK1 is needed to facilitate the transfer of the phosphate [68]. This supports the notion that 
PINK1 provides protection from apoptotic cell death in certain stress conditions [66]. It is 
difficult to look at PINK1 function without considering its interaction with parkin. This 
relationship was first established when looking at the remarkable phenotype similarities that 
PINK1 and parkin mutant flies shared. PINK1 mutants also show reduced ATP and mtDNA 
concentration leading to cell death. Experiments in flies showed that parkin overexpression 
suppressed the PINK1 mutation phenotype; however, PINK1 overexpression did not rescue 
parkin loss-of-function. This provides evidence that PINK1 and parkin act along the same 
pathway, where parkin is downstream of PINK1 [69,70,71].  
 
3.3.1 PINK1 Dysfunction 
 
Mutations in PINK1 are the second most common cause of the autosomal recessive, early-onset 
parkinsonism after parkin mutations [66]. Most of the mutations that cause disease are missense 
mutations at the kinase domain and interfere with its kinase activity. Similar to many other 
kinase proteins, PINK1 mutations cause deficiency in many different pathways and thus its 
effects on mitochondrial function and morphology are multifaceted. There are decreases in 
mitochondrial membrane potential, complex I and IV activity, ATP production, mitochondrial 
import and mtDNA levels, increases ROS production, and abnormal mitochondrial morphology 
[7]. Experiments generating Flag-tagged wild type L347P- or E417G-adenovirus to infect SH-
SY5Y cells, tested to see how mutant PINK1 impairs mitochondrial respiration and ATP 
synthesis. Post infection results observed a statistically significant defect in O2 consumption rate. 
The impaired electron transport chain also demonstrated that cells expressing these mutations 
had statistically significant reductions in mitochondrial ATP synthesis [73]. ATP is used as an 
energy source throughout the cell and as it pertains to PD, in the proteasomal activity. PD 
pathology is typically characterized by the presence of insoluble protein inclusions of -
Synuclein. These inclusions are often positive for polyubiquitin, a product of the ubiquitin 
proteasome system. The UPS is a tightly regulated pathway to target proteins by the 26S 
proteasome and with most proteases, it requires ATP [74]. PINK1 mutants’ impairment of the 
ATP synthesis was found to have effects on proteasome function. L347P-PINK1 and E417G-
PINK1 led to decreased degradation of a proteasome substrate. Results also showed that loss of 
PINK1 led to increased SDS-insoluble aggregates in both the wild type α-synuclein and the 




The DJ-1 gene encodes for a 189-amino acid protein. This protein has been associated with rare 
cases of early onset autosomal recessive PD [75]. DJ-1 is associated with the ThiJ/PfpI family, 
which has chaperone activity, and shares structural similarities with E. coli chaperone Hsp31 
[76]. In humans, DJ-1 forms a homodimer with a six-strand parallel beta-sheet sandwich by 
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alpha-helical arrangements. DJ-1 belongs to the protein superfamily but has key differences that 
contribute to its unique mechanism. DJ-1 contains a distorted catalytic triad for protease activity 
and its active site is blocked by an additional C-terminal helix. The dimer that it forms also 
varies from other members of the superfamily [77]. The catalytic triad varies at residues E18. 
C106, and H126, but the variation at C106 was interesting because it appeared to form a strained 
main-chain conformation and was easily oxidized [78]. This information is pertinent as it 
pertains to DJ-1 because of its role as a redox-activated chaperone [79]. DJ-1 is expressed 
throughout the body and has diverse biological roles in male fertility, oncogenesis, and 
neuroprotection. Like parkin, DJ-1 primarily localizes in the cytosol but also exists in the nucleus 
and mitochondria [80]. This subcellular localization relates to signal transduction, transcriptional 
regulation, and during stress, mitochondrial dysfunction [77]. DJ-1 is a regulator of antioxidative 
gene induction, during oxidative stress, DJ-1 expression increased the transcription and 
enzymatic activity of glutamate cysteine ligase (GCL), the rate limiting enzyme of glutathione 
biosynthesis. Glutathione plays a central role in maintaining cellular redox status and protecting 
cells from oxidative injury. In the presence of A53T mutant -Synuclein, DJ-1 activates the 
molecular chaperone Hsp70 to block -Synuclein aggregation and toxicity [81]. DJ-1 can be 
SUMOylated (SUMO = small ubiquitin-like modifiers) by PIASx-alpha, a SUMO ligase, to fully 
activate DJ-1. SUMOylated DJ-1 influences regulation in the vital p53 pathway by repressing 
p53 transcriptional activity thus decreasing Bcl-2 associated X protein expression and prevent 
ultraviolet induced cell death [82]. DJ-1 plays an indirect role in general mitochondrial 
maintenance through its synergistic transcriptional activities with PGC-1 However, DJ-1 does 
not directly interact with PGC-1, rather it stimulates PGC-1 activity through pyrimidine tract-
binding protein-associated splicing factor (PSF). PSF binds to PGC-1 and suppresses its 
transcriptional activity. DJ-1 prevents this repression by inhibiting the SUMOylation of PSF 
[83]. DJ-1 displays direct cytoprotective functions against mitochondrial ROS with a quenching 
effect. DJ-1 oxidation is needed to activate the protein and an in vitro assay showed that DJ-1 
eliminated hydrogen peroxide by oxidizing itself [84]. However, DJ-1 may exert its antioxidative 
effects to larger degree by influencing antioxidative gene regulation. DJ-1 stabilizes Nrf2, a 
master regulator of antioxidant transcriptional responses, by associating with its inhibitor Keap1 
and preventing ubiquitination [85].  
 
3.4.1 DJ-1 Dysfunction 
 
DJ-1 became associated with neurodegeneration when it was discovered as the PARK7 gene 
causing autosomal-recessive juvenile parkinsonism. The first described large genomic deletion 
that impaired the DJ-1 coding region was L166P, which causes severe destabilization of the 
protein. The severe L166P mutation disrupts the alpha-helix G of the structurally important C-
terminal helix-kink-helix motif and functional loss of DJ-1 [86,87]. The presence of L166P DJ-1 
resulted in the native isoform of DJ-1 being doubled. The mutation blocks dimerization and the 
monomer form are more rapidly degraded, leaving less functional DJ-1. The interaction with DJ-
1 and GCL is essential in protecting the cell from oxidative stress. Mutations in DJ-1 causes a 
decrease in glutathione which results in oxidative stress and increased cytotoxicity. Experiments 
confirmed that L166P DJ-1 showed no protection against protein oxidation when compared with 
controls. It is also important to note that increased glutathione was specifically linked to 
increased survival of both primary dopamine neurons and dopamine cell lines. This impaired 
glutathione recruitment by DJ-1 mutation may assist the development of PD in patients with 
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other pathogenic factors [81]. DJ-1 mutation at Lys130 was unable to regulate androgen receptor 
activity, Lysine 130 seems to be SUMOylated and the modification seems to be necessary for 
full activity [88]. Oxidative stress by ROS rendered DJ-1 incapable of inhibiting SUMOylation 
on PSF and thus PGC-1 activity was reduced [83]. DJ-1 mutant cells (R89Q, D149A, and 
L166P) had significantly increased levels of DLP1, a mitochondrial fission protein. Changes in 
mitochondrial morphology was found to have an influence on mitochondrial function. In cells 
with DJ-1 mutant variants, there was an increase in the ROS levels and a decrease in ATP and 
mitochondrial membrane potential. This dysfunction was also replicated in well-differentiated 
neurons (rat E18 primary cortical neurons), where samples containing the mutant variants saw 




The Leucine-rich repeat kinase 2 (LRRK2) gene encodes a large multidomain protein composed 
of 2527 amino acids. The functional domains that the protein consist of are a kinase domain that 
is a part of the mixed lineage kinase family, a Roc domain with similarity to the Ras/GTPase 
superfamily, a COR domain, a WD40-repeat domain, and leucine rich repeats [90]. Purified 
LRRK2 has been shown to be dimeric, allowing for self-interaction. The two monomers lie in a 
head-to-tail orientation with large sections of the molecules interacting to stabilize the dimer 
[91,93]. It has also been argued that either the Roc domain or the COR domain provide the 
primary interaction motif [92]. The N- and C- terminal regions of LRRK2 contribute to the 
interactions around the central portion of the molecule that binds GTP. Further research is 
needed to see what contributes to LRRK2’s self-interaction. What has been established is that in 
the dimerization process, one of the posttranslational modifications that occurs is 
autophosphorylation. Autophosphorylation has been observed to activate LRRK2 
serine/threonine kinase activity [93]. However, the kinase domain in the structure provided by 
[91] shows that it is positioned towards the solvent, meaning that it may not be strictly a cis-
acting event [92]. LRRK2 is known to phosphorylate a variety of proteins, one potential 
substrate is the Rab family of small GTPases. In particular, Rab10, which regulates intracellular 
vesicular transport. This protein family functions as a molecular switch in the tethering, docking, 
fusion, and motion of intracellular membranes [94]. Rab GTPase refers to a family of proteins 
and while Rab10 has this set of functions, Rab32 was shown to interact with mitochondria. 
LRRK2 can bind to the outer mitochondrial membrane and about 10% of overexpressed LRRK2 
was associated with the outer mitochondrial membrane [7]. Rab32 also has roles in trafficking, 
they help assemble complexes used for fission and fusion. Rab32 localizes to the mitochondria 
and contributes to mitochondrial fission [95]. LRRK2 morphology regulation is not limited to the 
mitochondria, there is also evidence that LRRK2 is involved in neuronal maintenance [99]. 
 
3.5.1 LRRK2 Dysfunction 
 
Pathogenic PD LRRK2 mutations predominantly map to the kinase and the Roc-COR (GTPase) 
domains. Other PD risk factors in coding mutations are found in the WD40 domain. The 
mutations in the catalytic Roc-COR and kinase domains of LRRK2 are a common cause of 
familial PD. LRRK2 missense mutations seem to be the most commonly known genetic cause of 
PD. The mutations seem to induce an increase in LRRK2 kinase activity and a decrease in the 
GTPase activity. Cell and animal models support the model that LRRK2 mutations affect 
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vesicular trafficking, autophagy, protein synthesis, and cytoskeletal function. It has been 
established that G2019S mutation increases LRRK2 kinase activity (in autophosphorylation and 
phosphorylation of substrates) and that toxicity is dependent on this increased activity, 
suggesting a gain of function mechanism [7,96]. Studies with mutant LRRK2 at the GTPase 
domain P-loop reveal that a function Roc GTPase domain is necessary for kinase activity, 
suggesting that GTP binding may regulate kinase activity [97]. In a C. elegans model 
dopaminergic neurons were particularly sensitive to mutant LRRK2. Specifically, the G2109S 
variant increased the vulnerability of dopaminergic neurons compared to wild type [98]. 
Overexpression of G2019S led to a dramatic reduction in neurite length and branching, as well as 
overall neurite growth. At the later time points the cells expressing the mutants had decreased 
neuron survival [99]. This change in morphology may have to do with LRRK2’s physical and 
function interaction with protein translation machinery. PD-linked LRRK2 mutations altered 
protein synthesis and are toxic [96]. Pathogenic LRRK2 influences mRNA translation by 
negatively regulating miRNA activity [100]. LRRK2 dysfunction also impedes vesicle 
trafficking, leading to neuronal dysfunction. G2019S was reported to over phosphorylate 
endophilin A, which is required for the endocytosis of synaptic vesicles. Hyper phosphorylating 
endo A resulted in impaired vesicle recycling [101]. Mutant LRRK2 associates with autophagic 
vesicles and multivesicular bodies in the human brain, this causes a disruption of autophagy in 
midbrain dopamine neurons leading to eventual neuronal death and locomotor deficits. LRRK2 
is typically degraded using the UPS or CMA, but the mutant variant impedes the CMA and 
inhibits the uptake of other substrates. This is potentially mechanism of toxicity. Like -
Synuclein, LRRK2 mutations exist in LBs [96]. This link between -Synuclein and LRRK2 in 
neuropathology is supported by evidence that overexpressed LRRK2 promotes aggregation and 
toxicity of -Synuclein in A53T mice, while LRRK2 KO blocked toxicity [102]. The stimulatory 
action of pathogenic LRRK2 on mRNA translation could be an explanation for increased -
Synuclein or pathogenic LRRK2 may promote oligomerization of -Synuclein on the lysosomal 
surface and impair its uptake through chaperone-mediated autophagy and subsequent 
degradation [103,104]. 
 
4. ER Stress Signaling 
 
One of the main functions of the ER is to initiate protein folding in the secretory pathway. The 
mechanism is complex and dynamic, consisting of a network of protein chaperones, foldases, 
and co-factors at the ER lumen to catalyze the folding and maturation of proteins [112]. The ER 
plays a vital role in cellular protein quality control by extracting and degrading proteins that are 
not correctly folded or assembled into native complexes, this process is known as ER-associated 
degradation (ERAD), checks that only properly folded and assembled proteins are transported to 
the final destination [113]. The accumulation of diffusible oligomer or large aggregates of 
misfolded proteins is a key characteristic of many neurodegenerative diseases. Fluctuations in 
protein homeostasis leading to these accumulations is a major factor underlying the pathology of 
brain disease-linked proteins. This suggests that perturbation in ER function is a common event 
in PD. Decreasing protein aggregation or reducing the effects of downstream signaling are 
thought to be relevant mechanisms for therapy [105]. Misfolded proteins exert stress onto the 
endoplasmic reticulum (ER) which is mitigated by the actions of the unfolded protein response 
(UPR). The ER stress response is aimed to protect the cells against toxic build-up of misfolded 
proteins. Several conditions can incite the UPR, such as, hypoxia, glucose deprivation, oxidative 
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stress, viral infection, high fat or cholesterol, and mutations in specific proteins The UPR is a 
complex signal transduction pathway that modulates the expression of proteins. These proteins 
are involved in a wide range of functions including folding, quality control, protein entry into the 
ER, and organelle biogenesis. The UPR regulates transcription and translation of genes that 
mediate these functions to re-establish homeostasis and ER function. The ER is associated with 
UPR through stress receptors on the ER membrane. The receptors transduce information about 
the protein folding status in the ER lumen to the nucleus and cytosol by regulating expression of 
transcription factors and other proximal signaling substrates [106,113]. There are three main 
types of ER resident transmembrane signaling proteins that operate as stress sensors that activate 
UPR signaling responses. These sensors include double stranded RNA-activated protein kinase-
like endoplasmic reticulum kinase (PERK), activating transcription factor 6 (ATF-6), and 
inositol requiring kinase 1 (IRE-1) [105]. UPR is initiated by the binding of the ER chaperone 
BiP/GRP78 to misfolded proteins. Under normal conditions, BiP/GRP78 forms a complex with 
three other key proteins at the ER membrane, PERK, transcription factor ATF-6, and 
endoribonuclease IRE-1. By binding BiP/GRP78 to the misfolded protein, PERK, ATF-6, and 
IRE-1 are released from BiP/GRP78 and activated. PERK homodimerizes and 
autophosphorylates to phosphorylate eukaryotic initiation factor 2-alpha (peIF2alpha). The role 
of peIF2alpha is to decrease the frequency of mRNA translation initiation and reduce the overall 
protein load on the ER; however, it also increases the translation of specific mRNAs, such as 
activating transcription factor 4 (ATF4). ATF4 activates transcription of genes involved in amino 
acid metabolism and transport, redox reactions, and ER stress induced apoptosis [107]. IRE-1 is 
a serine/threonine protein kinase and endoribonuclease that regulates the unconventional splicing 
of the mRNA for transcription factor X-Box Binding protein-1 (XBP-1). XBP-1 translocates to 
the nucleus and controls the expression of UPR-related genes that function in protein quality 
control, folding, the ERAD system, and ER and GA biogenesis. IRE-1 has other functions in cell 
signaling, initiating the activation of alarm pathways mediated by Apoptosis Signal-regulating 
Kinase 1 (ASK1) and c-Jun-N terminal kinase (JNK) pathway. This pathway is the result of 
prolonged ER stress [105]. 
 
4.1 ER Stress Defense Mechanisms 
 
Misfolded proteins play a central role in neuronal cell loss in PD. These proteins may inhibit 
synaptic function, interfere with signal transduction pathways, cause dysfunction of protein 
degradation through the ubiquitin proteasome system (UPS), and cause eventual cell death [108]. 
An important effect of the UPR is the up regulation of ERAD components. ERAD maintains ER 
homeostasis by eliminating misfolded proteins, protein subunits that fail to assemble into their 
native complexes, and proteins whose levels must be acutely regulated in response to metabolic 
needs [113]. ERAD can be broken down into three interdependent components: 1) recognition of 
the protein target and its association with the appropriate luminal chaperones, 2) association with 
ERAD ubiquitylation machinery, and 3) retrotranslocation into the cytosol for degradation by 
proteasomes [114]. Mammalian ERAD is complex and contains many redundancies, this causes 
different ERAD pathways to overlap; however, the overall mechanism involves ubiquitin ligases 
that attach polyubiquitin chains to proteins as signal for degradation [108]. UPR is initially 
activated in PD pathogenesis for neuroprotection, to remove the toxic unfolded proteins; 
however, the prolonged ER stress and UPR activation overwhelms the protective machinery, 
leading to cell death [108]. CEBP homologous protein (CHOP) is a proapoptotic transcription 
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factor that is induced through the PERK-eIFalpha pathway. CHOP is activation is induced by 
peIFalpha recruitment of ATF4, CHOP affects the expression of genes favoring apoptosis in 
response to ER stress [111]. Autophagy has been proposed as a protective mechanism to 
overcome neurodegeneration and is modulated by ER stress. Autophagy is induced by many of 
the same conditions as ER stress and is a catabolic process that mediates the degradation of 
proteins and dysfunctional organelles. It can be divided into three main types: 1) 
macroautophagy, 2) microautophagy, and 3) chaperone-mediated autophagy (CMA). While 
autophagy is considered to be non-selective in the degradation of bulk cytoplasmic components, 
in some cases it displays substrate specificity. Selective degradation of mitochondria 
(mitophagy) is particularly important due to its increased association with PD pathogenesis 
through the PINK1-parkin pathway. -Synuclein in its native form is degraded using CMA, the 
protein contains a 15 amino acid sequence that consists of overlapping variations of the KRERQ 
CMA recognition motif. The chaperone HSC70 recognizes the motif and binds to -Synuclein. 
-Synuclein then binds to the lysosomal-associated membrane protein type 2A (LAMP-2A) at 
the lysosomal membrane. The CMA receptor along with the chaperone transports -Synuclein 
into the lysosome for degradation [117]. 
 
4.2 ER Stress Factors 
 
Activation of UPR was investigated with immunohistochemistry for pPERK and peIF2alpha. 
Results found that both proteins were found in the neurons of PD patients but not controls. A 
connection between pPERK and -Synuclein was also found, in PD cases there was a strong 
colocalization in neuromelanin containing neurons in the substantia nigra. Interestingly, pPERK 
was only observed in neurons containing -Synuclein, but not all neurons containing -
Synuclein had pPERK present. This suggests a functional connection between -Synuclein 
pathology and the occurrence of ER stress [108]. -Synuclein can induce ER stress with a 
variety of mechanisms. Overexpression of A53T -Synuclein leads to the formation of 
cytoplasmic aggregates and disrupts the UPS [109,110]. The cell’s impaired ability to degrade 
proteins leads to a buildup of misfolded proteins in the ER and making the cell more vulnerable 
to ER stress [108]. Additional experiments have demonstrated that the earliest defect following 
-Synuclein expression is a block in ER to Golgi vesicular trafficking. The inhibition of ER to 
Golgi trafficking induces ER stress through the accumulation of cargo vesicles, triggering the 
buildup of immature proteins at the ER [115,116]. The various mutant forms of -Synuclein 
vary in the degree to which they inhibit the lysosomal/CMA degradation pathway and thus have 
different levels of toxicity [117]. A53T and A50P mutants bind tightly to the LAMP-2A receptor 
but cannot be transported across the lysosomal membrane [118]. These mutants act as receptor 
inhibitors, preventing other CMA substrates from binding, resulting in a complete block of CMA 
and a higher degree of toxicity. Blocking CMA activity with mutant -Synuclein not only results 
in the direct buildup of toxicity in the neuron through the formation of aggregates, but it also 
prevents the protective activity of myocyte enhancer factor 2D (MEF2D). MEF2D is a 
transcription factor in neuronal survival. CMA degradation regulates MEF2D activity and when 
CMA is inhibited, an inactive form of the protein is present in the cytosol but not the nucleus. 
This inactive form cannot bind DNA and -Synuclein prevents Hsc70 from binding to MEF2D. 
-Synuclein not only promotes neuronal death by forming aggregates, but it also promotes cell 
death by inhibiting cell survival proteins [117,119]. As was mentioned before, parkin is involved 
in both the ubiquitin-proteasome pathway and cell death protection. Parkin dysfunction not only 
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exerts the pressure onto cells through its own inaction, but it causes a higher demand from the 
ER stress mechanisms like UPS. This leads to prolonged ER stress and cell death that follows it. 
This is backed up by the finding that Pael-R, a parkin substrate, triggers ER stress in vivo and in 




Although Parkinson’s disease is the second most prevalent neurodegenerative disease 
behind Alzheimer’s disease, prevention and treatment of PD remains uncompleted. PD is 
characterized by the accumulation of misfolded proteins and the death of dopaminergic neurons; 
however, cell death is the end result of numerous interconnected pathways. Considering only one 
pathway for a potential therapy gives a fragmented image of the solution. This is the current 
predicament towards finding a solution. Recent research has identified genes that are associated 
with PD pathogenesis, specifically their function and more importantly dysfunction. These PD-
associated genes (parkin, PINK1, DJ-1, LRRK2) have provided new insights into the 
biochemical pathways that lead to disease progression. While these genes are not encoded by 
mtDNA, their function is closely related to mitochondrial homeostasis. Mutations in any one of 
these genes produces either a dysfunctional protein or a misfolded protein. Due to the nature of 
the mitochondrial environment and the oxidative respiratory chain, DNA is prone to mutations. 
Dysfunctional proteins damage the mitochondria causing complications. Complex I impairment 
generates ROS, causing a positive feedback loop that propagates oxidative stress. Manifold 
facets of neuron biology are affected in PD, the primary effector of dysfunction could be any of 
these genes and much more work is needed to figure out how the pieces of the puzzle fit 
together, and, in this analogy, even mitochondrial dysfunction is only a part of the puzzle. The 
results of mitochondrial-associated protein misfolding leads to a cascade of dysfunction 
throughout the cell. 
  -Synuclein has also been recently explored as a therapeutic target. Lewy bodies are a 
cardinal feature of the PD and -Synuclein aggregates have been found present in high 
concentrations within the inclusions. LBs are the accumulation of misfolded and aggregated 
proteins, especially the ubiquitin protein. This protein is widely used across cells as tag for 
degradation. The increased concentration of misfolded protein generates ER stress and generally, 
the cell would utilize the Unfolded Protein Response to mediate protein dysfunction through the 
Ubiquitin Proteasome System. The accumulation of ubiquitin and misfolded proteins indicates 
dysfunction within the cells’ normal degradation system. This problem is compounded when 
mutations in genes that cause mitochondria dysfunction, such as parkin, a ubiquitin ligase, are 
introduced. The inability of parkin to tag its substrates for degradation leads to a buildup of 
proteins causing further ER stress. The accumulation of these stressors induces chronic ER 
stress, resulting in dopaminergic neuron death. 
 
5.1 Future Directions 
 
Recent research has targeted -Synuclein therapy, its dysfunction is a factor in many of 
the pathways towards PD. Several potential solutions have been suggested to mitigate the 
influence of -Synuclein. One is to find a molecule that stabilizes the intrinsically disordered 
conformation of -Synuclein or block its aggregation potential to disaggregate the aggregates 
back down to the monomeric state. Alternatively, look for chemical compounds that can either 
 16 
clear toxic misfolded proteins or protect neurons from the effect of toxic proteins [122]. Finally, 
and somewhat counterintuitively is the rapid promotion of protein aggregates. Recent evidence 
has shown that the rapid formation of large inclusions might have a neuroprotective role, and the 
molecules that stimulate the formation of these large protein aggregates could be used as a 
therapeutic means for affected neurons [123].  
Considering the important role of mitochondria in energy metabolism, calcium 
homeostasis, cellular quality control pathways and cell death regulation, it is vital to consider 
that mitochondrial dysfunction highly contributes to dopaminergic neuron vulnerability [7]. 
These neurons with high mitochondrial dysfunction exhibit a high oxidative burden, thus 
antioxidants should be considered as a treatment target. Another interesting area of research is 
the role of calcium in mitochondria homeostasis, and mitochondria’s role in regulating calcium 
homeostasis. An imbalance in calcium buffering seems to be causally related to the selective 
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